<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> is a poor prognostic indicator in the <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Treatment options for patients with symptomatic <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> are limited </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi>, an attenuated <z:chebi fb="3" ids="50113">androgen</z:chebi>, may have some efficacy in increasing the platelet count of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We retrospectively reviewed 33 patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> who were treated with <z:chebi fb="1" ids="4315">danazol</z:chebi> for 6 or more weeks </plain></SENT>
<SENT sid="4" pm="."><plain>After 6 weeks on <z:chebi fb="1" ids="4315">danazol</z:chebi>, the mean <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">platelet count increased</z:e> from 42 x 10(9)/L to 60 x 10(9)/L (P &lt; 0.015), and 25 out of 33 patients (76%) had an increase in their platelet counts </plain></SENT>
<SENT sid="5" pm="."><plain>Following 12 weeks of treatment, the mean <z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">platelet count increased</z:e> to 67 x 10(9)/L (P &lt; 0.005), and 21 out of 29 patients (72%) had an increase in their platelet counts </plain></SENT>
<SENT sid="6" pm="."><plain>Seven out of nine patients no longer required platelet transfusions because <z:mp ids='MP_0001914'>bleeding</z:mp> stopped after 6 weeks on <z:chebi fb="1" ids="4315">danazol</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Mean duration of response was 10 months (range 2-68 months) </plain></SENT>
<SENT sid="8" pm="."><plain>Responses were seen in <z:hpo ids='HP_0000001'>all</z:hpo> French-American-British (FAB) subtypes and in <z:hpo ids='HP_0000001'>all</z:hpo> International Prognostic Scoring System (IPSS) scores </plain></SENT>
<SENT sid="9" pm="."><plain>Therapy was well tolerated </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="1" ids="4315">Danazol</z:chebi> may be effective in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients who are thrombocytopenic </plain></SENT>
</text></document>